All Stories

  1. Potent HPIV3-neutralizing IGHV5-51 Antibodies Identified from Multiple Individuals Show L Chain and CDRH3 Promiscuity
  2. Data from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  3. Data from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  4. FIGURE 1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  5. FIGURE 1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  6. FIGURE 2 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  7. FIGURE 2 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  8. FIGURE 3 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  9. FIGURE 3 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  10. FIGURE 4 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  11. FIGURE 4 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  12. FIGURE 5 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  13. FIGURE 5 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  14. FIGURE 6 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  15. FIGURE 6 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  16. TABLE 1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  17. TABLE 1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  18. Table S1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  19. Table S1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  20. Development of an anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
  21. De novo sequencing and construction of a unique antibody for the recognition of alternative conformations of cytochrome c in cells
  22. Real-time cell analysis: A high-throughput approach for testing SARS-CoV-2 antibody neutralization and escape
  23. Neutralizing antibodies protect mice against Venezuelan equine encephalitis virus aerosol challenge
  24. Neutralization Fingerprinting Technology for Characterizing Polyclonal Antibody Responses to Dengue Vaccines
  25. Human antibody recognition of H7N9 influenza virus hemagglutinin following natural infection
  26. Protective pan-ebolavirus combination therapy by two multifunctional human antibodies
  27. A Requirement for p120-catenin in the metastasis of invasive ductal breast cancer
  28. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein
  29. p120-Catenin is an obligate haploinsufficient tumor suppressor in intestinal neoplasia
  30. Characterizing Antibodies
  31. Isotype Determination of Rodent-Derived Monoclonal Antibodies Using Sandwich ELISA
  32. Using Small Case-Based Learning Groups as a Setting for Teaching Medical Students How to Provide and Receive Peer Feedback
  33. Structural Insights into Reovirus σ1 Interactions with Two Neutralizing Antibodies
  34. Anti-MTG16 antibodies reveal MTG16 subcellular distribution and nucleocytoplasmic transport in erythroleukemia cells
  35. Kaiso Directs the Transcriptional Corepressor MTG16 to the Kaiso Binding Site in Target Promoters
  36. Monoclonal Antibodies to DIPA: A Novel Binding Partner of p120-Catenin Isoform 1
  37. p120-catenin is essential for terminal end bud function and mammary morphogenesis
  38. Selection of Monoclonal Antibodies Against 6-oxo-M 1 dG and Their Use in an LC-MS/MS Assay for the Presence of 6-oxo-M 1 dG in Vivo
  39. Faculty Opinions recommendation of Zeppo1 is a novel metastasis promoter that represses E-cadherin expression and regulates p120-catenin isoform expression and localization.
  40. Abstract 4157: Identification and validation of galectin-7 as a novel blood biomarker for NSCLC diagnosis
  41. ReCLIP (Reversible Cross-Link Immuno-Precipitation): An Efficient Method for Interrogation of Labile Protein Complexes
  42. The Molecular Evolution of the p120-Catenin Subfamily and Its Functional Associations
  43. Faculty Opinions recommendation of Heterozygous deficiency of delta-catenin impairs pathological angiogenesis.
  44. Faculty Opinions recommendation of Dynamic and static interactions between p120 catenin and E-cadherin regulate the stability of cell-cell adhesion.
  45. Faculty Opinions recommendation of Plakophilin 1 stimulates translation by promoting eIF4A1 activity.
  46. Faculty Opinions recommendation of Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer.
  47. p120-Catenin and p190RhoGAP Regulate Cell-Cell Adhesion by Coordinating Antagonism between Rac and Rho
  48. p120 serine and threonine phosphorylation is controlled by multiple ligand–receptor pathways but not cadherin ligation
  49. Regulation of cadherin stability and turnover by p120ctn: implications in disease and cancer
  50. Vectors and gene targeting modules for tandem affinity purification inSchizosaccharomyces pombe